Clearly, the drug-sensitizing effect of RFC11 in cancer cells is noticeable which is reflected in its synergistic anticancer effect and for its very prominent simultaneous upregulation of RIPK1 and RIPK3 expressions, as are evident in cellular and tumor levels. This evidence concerns the gene RIPK1 and neoplasm.